Regulatory T cells: A review of manufacturing and clinical utility

Tewodros Mamo; Keli L. Hippen; Margaret L. MacMillan; Claudio G. Brunstein; Jeffrey S. Miller; John E. Wagner; Bruce R. Blazar; David H. McKenna

doi:10.1111/trf.16797

Regulatory T cells: A review of manufacturing and clinical utility

Tewodros Mamo, Keli L. Hippen, Margaret L. MacMillan, Claudio G. Brunstein, Jeffrey S. Miller, John E. Wagner, Bruce R. Blazar, David H. McKenna

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	904-915
Number of pages	12
Journal	Transfusion
Volume	62
Issue number	4
DOIs	https://doi.org/10.1111/trf.16797
State	Published - Apr 2022

Bibliographical note

Funding Information:
This work was supported by the Production Assistance for Cellular Therapies (PACT) program from NIH/NHLBI at University of Minnesota Molecular and Cellular Therapeutics Facility, PACT Contract # HHSN268201000008C. This publication was also supported by the NCI grant P01 CA065493. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
BRB receives remuneration as an advisor to Magenta Therapeutics and Blue Rock Therapeutics; Research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre, Carisma, and is a co‐founder of Tmunity Therapeutics. CGB and JEW received research funding from BlueRock Therapeutics. TM, KLH, MLM, JSM, and DHM have disclosed no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Keywords

Humans
Quality Control
T-Lymphocytes, Regulatory

PubMed: MeSH publication types

Review
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1111/trf.16797

Find It

Find It at U of M Libraries

Cite this

@article{80aa309e8e7d4f90bce260863ba3c7dc,

title = "Regulatory T cells: A review of manufacturing and clinical utility",

keywords = "Humans, Quality Control, T-Lymphocytes, Regulatory",

author = "Tewodros Mamo and Hippen, {Keli L.} and MacMillan, {Margaret L.} and Brunstein, {Claudio G.} and Miller, {Jeffrey S.} and Wagner, {John E.} and Blazar, {Bruce R.} and McKenna, {David H.}",

note = "Funding Information: This work was supported by the Production Assistance for Cellular Therapies (PACT) program from NIH/NHLBI at University of Minnesota Molecular and Cellular Therapeutics Facility, PACT Contract # HHSN268201000008C. This publication was also supported by the NCI grant P01 CA065493. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: BRB receives remuneration as an advisor to Magenta Therapeutics and Blue Rock Therapeutics; Research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre, Carisma, and is a co‐founder of Tmunity Therapeutics. CGB and JEW received research funding from BlueRock Therapeutics. TM, KLH, MLM, JSM, and DHM have disclosed no conflicts of interest. The authors alone are responsible for the content and writing of the article.",

year = "2022",

month = apr,

doi = "10.1111/trf.16797",

language = "English (US)",

volume = "62",

pages = "904--915",

journal = "Transfusion",

issn = "0041-1132",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Regulatory T cells

T2 - A review of manufacturing and clinical utility

AU - Mamo, Tewodros

AU - Hippen, Keli L.

AU - MacMillan, Margaret L.

AU - Brunstein, Claudio G.

AU - Miller, Jeffrey S.

AU - Wagner, John E.

AU - Blazar, Bruce R.

AU - McKenna, David H.

N1 - Funding Information: This work was supported by the Production Assistance for Cellular Therapies (PACT) program from NIH/NHLBI at University of Minnesota Molecular and Cellular Therapeutics Facility, PACT Contract # HHSN268201000008C. This publication was also supported by the NCI grant P01 CA065493. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: BRB receives remuneration as an advisor to Magenta Therapeutics and Blue Rock Therapeutics; Research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre, Carisma, and is a co‐founder of Tmunity Therapeutics. CGB and JEW received research funding from BlueRock Therapeutics. TM, KLH, MLM, JSM, and DHM have disclosed no conflicts of interest. The authors alone are responsible for the content and writing of the article.

PY - 2022/4

Y1 - 2022/4

KW - Humans

KW - Quality Control

KW - T-Lymphocytes, Regulatory

UR - http://www.scopus.com/inward/record.url?scp=85122860751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122860751&partnerID=8YFLogxK

U2 - 10.1111/trf.16797

DO - 10.1111/trf.16797

M3 - Review article

C2 - 35015309

AN - SCOPUS:85122860751

SN - 0041-1132

VL - 62

SP - 904

EP - 915

JO - Transfusion

JF - Transfusion

IS - 4

ER -

Regulatory T cells: A review of manufacturing and clinical utility

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Cite this